Unknown

Dataset Information

0

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).


ABSTRACT: To evaluate transient, large visual acuity (VA) decreases, termed sporadic vision loss, during anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD).Cohort within a randomized clinical trial.setting: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). study population: Total of 1185 CATT patients. main outcome measures: Incidence of sporadic vision loss and odds ratio (OR) for association with patient and ocular factors. Sporadic vision loss was a decline of ?15 letters from the previous visit, followed by a return at the next visit to no more than 5 letters worse than the visit before the VA loss.There were 143 sporadic vision loss events in 122 of 1185 patients (10.3%). Mean VA at 2 years for those with and without sporadic vision loss was 58.5 (?20/63) and 68.4 (?20/40) letters, respectively (P < .001). Among patients treated pro re nata, no injection was given for 27.6% (27/98) of sporadic vision loss events. Multivariate analysis demonstrated that baseline predictors for sporadic vision loss included worse baseline VA (OR 2.92, 95% confidence interval [CI]:1.65-5.17 for ?20/200 compared with ?20/40), scar (OR 2.21, 95% CI:1.22-4.01), intraretinal foveal fluid on optical coherence tomography (OR 1.80, 95% CI:1.11-2.91), and medical history of anxiety (OR 1.90, 95% CI:1.12-3.24) and syncope (OR 2.75, 95% CI:1.45-5.22). Refraction decreased the likelihood of sporadic vision loss (OR 0.62, 95%CI: 0.42-0.91).Approximately 10% of CATT patients had sporadic vision loss. Baseline predictors included AMD-related factors and factors independent of AMD. These data are relevant for clinicians in practice and those involved in clinical trials.

SUBMITTER: Kim BJ 

PROVIDER: S-EPMC4301065 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Kim Benjamin J BJ   Ying Gui-Shuang GS   Huang Jiayan J   Levy Nicole E NE   Maguire Maureen G MG  

American journal of ophthalmology 20140413 1


<h4>Purpose</h4>To evaluate transient, large visual acuity (VA) decreases, termed sporadic vision loss, during anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD).<h4>Design</h4>Cohort within a randomized clinical trial.<h4>Methods</h4>setting: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). study population: Total of 1185 CATT patients. main outcome measures: Incidence of sporadic vision loss and odds ratio (OR) for a  ...[more]

Similar Datasets

| S-EPMC4151260 | biostudies-literature
| S-EPMC3737287 | biostudies-literature
| S-EPMC4467522 | biostudies-literature
| S-EPMC6462189 | biostudies-literature
| S-EPMC4254295 | biostudies-literature
| S-EPMC4998967 | biostudies-literature
| S-EPMC4458330 | biostudies-literature
| S-EPMC3633658 | biostudies-literature
| S-EPMC4766028 | biostudies-literature
| S-EPMC7082767 | biostudies-literature